Fetal Mesenchymal Stromal Cells: an Opportunity for Prenatal Cellular Therapy
Fetal Mesenchymal Stromal Cells: an Opportunity for Prenatal Cellular Therapy
复制标题
DOI：
10.1007/s40778-018-0118-8
复制
发表时间：
2018-03-01
影响因子：
1.4
通讯作者：
Westgren, Magnus
中科院分区：
文献类型：
--
作者：
Sagar, Rachel;Walther-Jallow, Lilian;Westgren, Magnus
本研究的目的是综述利用间充质间质细胞（MSCs）治疗产前先天性疾病的可能性。MSCs具有多谱系潜力和低免疫原性，具有免疫调节作用，更容易在培养中扩增。它们的迁移、移植和分化能力，或通过旁分泌作用作用于靶组织，使MSCs成为临床治疗的候选者。与成人来源的间充质干细胞相比，胎儿和胎外间充质干细胞具有更高的治疗潜力。通过超声引导下的脐带注射，MSCs可以在产前安全地移植。由于这些特点，胚胎间充质干细胞在子宫内干细胞移植治疗先天性疾病领域引起了极大的兴趣。
Purpose of Review The aim of the study is to provide an overview on the possibility of treating congenital disorders prenatally with mesenchymal stromal cells (MSCs).Recent Findings MSCs have multilineage potential and a low immunogenic profile and are immunomodulatory and more easy to expand in culture. Their ability to migrate, engraft and differentiate, or act via a paracrine effect on target tissues makes MSCs candidates for clinical therapies. Fetal and extra-fetal MSCs offer higher therapeutic potential compared to MSCs derived from adult sources.Summary MSCs may be safely transplanted prenatally via ultrasound-guided injection into the umbilical cord. Due to these characteristics, fetal MSCs are of great interest in the field of in utero stem cell transplantation for treatment of congenital disease.